§ Claim under review · Mixed
"David Sinclair believes humanity is only about 10 years away (by 2036) from technologies enabling people to live to 150, starting with a 2026 Phase 1 human trial of ER-100 for organ-by-organ epigenetic reprogramming beginning with the eyes." Post image text: "2026 / 2036; We're Only 10 Years Away From Living to 150."
Verdict
Partially accurate but misleading
Confidence
MediumSummary
The underlying science in this post is real, but the headline timeline is not supported. A company cofounded by Harvard's David Sinclair, Life Biosciences, did get FDA clearance in January 2026 and has dosed the first patients in a Phase 1 trial of a therapy called ER-100 for glaucoma and an optic nerve condition called NAION. That trial is a first-in-human safety study delivered to the eye, and it builds on a real 2020 Nature paper in which the same approach reversed vision loss in mice. Sinclair has genuinely said for over a decade that the first person to live to 150 may already be born, but that is a prediction about the next century, not about 2036. No source was found in which he says humanity is ten years away from 150-year lifespans, and the "2026 to 2036" graphic appears to be the poster's framing rather than his statement. The nearest comparable thing he has said publicly referred to roughly 120 years, not 150. What remains unknown is the actual result of the eye trial, since the first interim data were only scheduled for presentation around the time this post appeared.
The readings
key figures from the evidenceSinclair's nearest documented decade-scale age-reversal prediction
year of Nature paper on epigenetic reprogramming reversing vision loss in mice
Why this verdict
Evidence
The trial component of the claim is well supported. The ClinicalTrials.gov record describes a first-in-human, Phase 1 trial designed to evaluate the safety and tolerability of ER-100, an investigational epigenetic therapy candidate intended for age-related optic neuropathies such as open angle glaucoma and non-arteritic anterior ischemic optic neuropathy, with participants followed for up to five years to monitor long-term health and vision outcomes.
Life Biosciences announced FDA clearance of the IND application, allowing it to evaluate ER-100's safety and potential to improve vision in patients with optic neuropathies, with the Phase 1 first-in-human study registered as NCT07290244.
MIT Technology Review reported in January 2026 that ER-100 is a treatment created by Life Biosciences, a Boston startup Sinclair cofounded, which had won FDA approval to proceed.
Life Biosciences subsequently announced that the first participant had been dosed in the Phase 1 trial.
The company describes ER-100 as AAV2-OSK and states that if successful it would be the first time cells have been rejuvenated in humans.
The animal-research foundation is also real. The Nature 2020 paper reports that expression of three Yamanaka transcription factors in mouse retinal ganglion cells restores youthful DNA methylation patterns, promotes axon regeneration after injury, and reverses vision loss in a mouse model of glaucoma and in aged mice.
Sinclair's lab has also reported success in primates, and the human trial is the first time ER-100 has been given to people.
The "150" prediction is a real and long-standing Sinclair statement, but it is not new and is not dated to 2036. In August 2015, Sinclair, then co-director of a Harvard Medical School aging lab, was the subject of a story headlined "The first person to live to 150 has already been born."
Sinclair himself later posted that his prediction, which he worded as "it's possible the first person to reach 150 has already been born," had gone global, linking a January 2023 Harvard Gazette piece.
Wikipedia's longevity escape velocity entry records the same position, that Sinclair believes the first human who will live to 150 years has already been born.
I found no source in which Sinclair sets 2036, or "about 10 years from now," as the date by which technologies enabling 150-year lifespans will exist. The closest documented near-term timeline is different in both number and meaning: in March 2024 Sinclair was reported as saying humans will be able to control biological age and reverse their age in 10 years with advances in medical science and live up to around 120 . That is a 120-year figure and a roughly 2034 horizon for biological age control, not a 150-year lifespan by 2036.
Findings
✓ What's accurate 7
- ER-100 exists and is a real investigational therapy from Life Biosciences, a company David Sinclair cofounded.
- A Phase 1 first-in-human trial (NCT07290244) did begin in 2026, after FDA IND clearance announced in January 2026, and the first patient has been dosed.
- The trial is in optic nerve disease, specifically open-angle glaucoma and NAION, consistent with "beginning with the eyes."
- The trial is primarily a safety and tolerability study, which the post's caption itself correctly acknowledges.
- The animal foundation is real: the 2020 Nature paper reports OSK-driven restoration of youthful methylation patterns and reversal of vision loss in mice.
- Sinclair has genuinely and repeatedly predicted that the first person to reach 150 may already be alive.
- A preclinical liver program (ER-300) exists, giving partial support to "expanding to the liver."
≈ What's misleading 8
- Temporal overreach and date fabrication in framing: the headline "We're Only 10 Years Away From Living to 150" and the 2026 to 2036 visual attach a specific near-term date to Sinclair's prediction. No source found has Sinclair saying 2036, or that 150-year lifespans become achievable within ten years. His actual prediction, that someone alive today may reach 150, implies a horizon around the 2100s to 2150s, not 2036.
- Internal contradiction created by the framing: a person alive in 2026 reaching 150 cannot be demonstrated by 2036. The graphic implies a decade-scale payoff that the underlying prediction does not contain.
- Number substitution: the nearest documented Sinclair decade-scale timeline refers to controlling and reversing biological age and living to around 120, not 150.
- Novelty framing: the post says "In 2026, he described a future in which..." The 150 prediction dates to at least 2015 and was widely covered in 2023. It is not a 2026 development.
- Scope inflation from eyes to whole body: the clinical evidence base is a single safety trial in one tissue, delivered locally to the eye. Liver work is mouse-stage. Lungs, joints, skin, and brain are aspiration with no verified program.
- Species extrapolation in the surrounding framing: vision restoration is a mouse and nonhuman primate result. No human efficacy result was available at the time of posting.
- Visual framing: an AI-generated de-aging image presented alongside a scientific claim invites readers to treat a speculative illustration as a depicted outcome.
- Note in fairness: the post's caption is substantially more careful than its headline and image. The caption explicitly states this is a bold prediction, not a proven outcome, that no treatment has extended human lifespan near 150, and that the trial is primarily testing safety in the eye. The distortion sits in the headline, the 2026/2036 graphic, and the claim text as circulated.
? What's uncertain 5
- Whether Sinclair said anything resembling "10 years" or "2036" in the cited James Altucher Show episode. I could not retrieve a transcript of that episode. The episode exists and is titled around the first human trial of an age-reversal therapy, but its contents were not verifiable in this session.
- The exact enrollment size, dosing cohorts, and current enrollment status of NCT07290244.
- The content of the October 2026 Eyecelerator interim data. The announcement of a presentation was found, the results were not.
- Whether Life Biosciences has any formal program in lungs, joints, skin, or brain.
- My search budget was exhausted after seven distinct queries, including two aimed specifically at the 2036 and ten-year framing. The absence-of-evidence findings above should be read with that limit in mind.
Sources
10 of 12 linked to recordsClinicalTrials.gov registry entry NCT07290244, "Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy"
Lu Y, Brommer B, Tian X, et al., "Reprogramming to recover youthful epigenetic information and restore vision," Nature 588:124-129 (2020)
Life Biosciences press release, "Announces First Patient Dosed in Phase 1 Trial of ER-100 for Optic Neuropathies"
Life Biosciences, "Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies"
MIT Technology Review, "The first human test of a rejuvenation method will begin 'shortly'" (Jan 27, 2026)
National Geographic, "Are We on the Brink of Ending Aging?"
GlobeNewswire (Oct 1, 2026), Life Biosciences to present first-in-human interim data at Eyecelerator 2026
The World / PRX (Aug 2015), "The first person to live to 150 has already been born"
Harvard Gazette (Jan 2023) "Has first person to live to be 150 been born?", referenced by Sinclair's own X post
KED Global (Mar 2024), "Reversing age possible in a decade: Harvard Prof. David Sinclair"
Life Biosciences ARDD 2025 presentation release (ER-300, liver)
Modern Wisdom episode #1141 listing and Lifeboat/Lifespan podcast summaries